Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies
- 1 November 2017
- journal article
- research article
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 109, S124-S131
Abstract
No abstract availableKeywords
Funding Information
- FDA Office of Orphan Products (R01FD003712, R01FD004363)
- Japan Research Foundation for Clinical Pharmacology
- Uehara Memorial Foundation
This publication has 34 references indexed in Scilit:
- Intravenous Temsirolimus in Cancer Patients: Clinical Pharmacology and Dosing ConsiderationsSeminars in Oncology, 2009
- Population pharmacokinetics of sirolimus inde novoChinese adult renal transplant patientsBritish Journal of Clinical Pharmacology, 2009
- Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and PharmacokineticsClinical Pharmacology & Therapeutics, 2009
- Pharmacokinetics of Mycophenolate Mofetil and Sirolimus in ChildrenTherapeutic Drug Monitoring, 2008
- Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic DataJournal of Clinical Oncology, 2008
- Rapamycin causes regression of astrocytomas in tuberous sclerosis complexAnnals of Neurology, 2006
- Sirolimus Population Pharmacokinetic/Pharmacogenetic Analysis and Bayesian Modelling in Kidney Transplant RecipientsClinical Pharmacokinetics, 2006
- Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune®, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis1Pediatric Transplantation, 2004
- Target concentration intervention: beyond Y2KBritish Journal of Clinical Pharmacology, 2001
- Model-Based, Goal-Oriented, Individualised Drug TherapyClinical Pharmacokinetics, 1998